Adjuvant Therapy in Node-Positive Endometrial Cancer: A Focus on Chemotherapy

Purpose of Review In advanced-stage and high-risk endometrial cancer, adjuvant treatment is the standard of care and typically includes chemotherapy with or without radiotherapy. Debate continues over the optimal use of these two treatment modalities together or separately. This review covers the historical literature leading to the current recommendation for adjuvant chemotherapy, in addition to looking forward to the relatively new field of targeted molecular treatment. Recent Findings The review covers recent phase III trials comparing chemotherapy to radiotherapy in high-risk endometrial cancer. Additionally, the era of genomic medicine has a new foothold in endometrial cancer, and the review covers new discoveries on molecular classification and prognostic implications. Fortunately, the majority of endometrial cancer has a good prognosis. For advanced-stage and high-risk histologies, the prognosis can be guarded, with adjuvant treatment improving outcomes. Gynecologic oncologists continue to debate the optimal treatment modality/modalities, a debate which will likely become more robust as the field of molecular treatment in endometrial cancer evolves.

Automated summary

This review explores the historical literature on adjuvant treatment in endometrial cancer and the ongoing debate over the optimal use of chemotherapy and radiotherapy. It also discusses recent findings on molecular classification and prognostic implications in the field of genomic medicine. While most endometrial cancer patients have a good prognosis, adjuvant treatment can improve outcomes for advanced-stage and high-risk histologies. The optimal treatment modality/modalities continue to be debated, especially with the advancements in molecular treatment for endometrial cancer.